Lucas Rodriguez rejoins Alacrita as partner

Lucas Rodriguez, PhD, has rejoined Alacrita, a Cambridge, MA-based life sciences consulting firm, as a partner.

Based in North Carolina’s Research Triangle, Rodriguez will bolster Alacrita’s biotech investment and fundraising advisory practice – which advises clients on opportunity assessment, capital strategy, company formation, investor relations, due diligence, and post-raise execution.

Rodriguez brings more than a decade of industry, consulting, and academic experience in biopharma. He spent the last two years at Doloromics, a discovery-stage biotech focusing on novel pain therapies, where he was CEO and chief business officer. Before that, Rodriguez spent a year as a consultant at Alacrita and five years as co-founder and CEO of CerSci Therapeutics, a neuroscience company that was acquired by Acadia Pharmaceuticals in 2020.

He was also previously a senior lecturer at his alma mater the University of Texas at Dallas.

Rodriguez has doctoral and master’s degrees in biomedical engineering from the University of Texas at Dallas and a bachelor’s degree in biology from Baylor University.

"Lucas has founded, led, and sold biotech companies, giving him an ideal perspective on both the investor and operator sides of the table," said Alastair Southwell, managing partner at Alacrita. "We are thrilled to welcome him back as a Partner, where he will drive our investment and fundraising advisory work and help clients achieve their most critical development milestones."

Rodriguez will expand Alacrita’s core team of professionals to 12 members. The firm leverages a wider network of 350+ experts who have spent their careers discovering, developing, manufacturing, and commercializing drug products.

Alacrita was founded in 2009 and has offices in Cambridge, MA and London, UK. The firm supports pharma and biotech firms – as well as investors and law firms – with product development, strategy and commercialization, business development, and expert witness services.